Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study
2023; Elsevier BV; Volume: 24; Issue: 5 Linguagem: Inglês
10.1016/s1470-2045(23)00097-9
ISSN1474-5488
AutoresToni K. Choueiri, David F. McDermott, Jaime R. Merchan, Todd M. Bauer, Robert A. Figlin, Elisabeth I. Heath, M. Dror Michaelson, Edward Arrowsmith, Anishka D'souza, Zhao Song, Ananya Roy, Rodolfo F. Perini, Donna Vickery, Scott S. Tykodi,
Tópico(s)Renal and related cancers
Referência(s)